Roche is among the first drugmakers to voice opposition to the transaction with potentially wide-ranging repercussions for weight-loss drugs based on the gut hormone GLP-1. "Limiting the ...

In an interview with Yahoo Finance, Deutsche Bank analyst James Shin singled out Roche’s (OTCMKTS: RHHBY) drug “CT-996” when asked about which oral weight loss drug he sees as the biggest ...

An experimental Alzheimer’s therapy from Roche successfully cleared a protein that’s a hallmark of the disease from patients’ ...

Roche has reported early-stage clinical data ... which revealed an average weight loss of 7.3% at four weeks in the study population of obese patients without diabetes, compared to a 1.2% ...

The Danish company’s share price rise of 7 per cent this year lags far behind its rival Eli Lilly’s 36 per cent, as the US company has gradually increased its share of the obesity and diabetes market ...

BioAge's weight loss candidate, azelaprag ... The Motley Fool recommends Amgen, Novo Nordisk, and Roche Holding AG. The Motley Fool has a disclosure policy.

Though it stressed on Wednesday it was not itself affected, Roche is among the first drugmakers to voice opposition to the transaction with potentially wide-ranging repercussions for weight-loss ...

The Swiss pharma company Roche is developing an oral GLP-1 weight loss drug. An analyst at Deutsche Bank recently referenced a drug as a threat to Eli Lilly's competing treatment. The drug has ...